Sanofi-Aventis Sa (SNY) 42.50 $SNY Amgen's Repatha Gains

New Post Public Reply Private Reply Replies (0) Message Board

Jul 12, 2016 at 6:07 PM

Sanofi-Aventis Sa (SNY) 42.50 $SNY

Amgen's Repatha Gains FDA Approval for New Dosing Option
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 9:20AM CDT
Amgen's (AMGN) PCSK9 inhibitor Repatha becomes the first and the only one to gain FDA approval for a monthly single-dose administration.
INVA: 11.76 (-0.01), AMGN: 161.96 (+1.78), SNY: 42.50 (+1.08), REGN: 368.75 (-6.99)

Sanofi Starts Olipudase Alfa Study, Praluent Ok'd in Japan
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:09AM CDT
Sanofi's (SNY) begins dosing of the first adult patient in a phase II/III study on olipudase alfa; Praluent gains approval in Japan.
INVA: 11.76 (-0.01), PFE: 36.24 (+0.09), SNY: 42.50 (+1.08), REGN: 368.75 (-6.99)

Blog Coverage Biotech Major Medivation Open to Takeover Talks
ACCESSWIRE - Wed Jul 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / July 6, 2016 / Active Wall St. blog coverage looks at the headline from Medivation Inc. (NASDAQ: MDVN) as the U.S. company signs confidentiality agreements with Paris-based Sanofi S.A. (NYSE: SNY), Pfizer Inc. (NYSE: PFE) and Celgene Corp. (NASDAQ: CELG) among others. Register with us now for your free membership and blog access at:
MDVN: 62.15 (-0.08), PFE: 36.24 (+0.09), ABBV: 65.50 (+1.15), SNY: 42.50 (+1.08), CELG: 103.41 (unch)

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
PR Newswire - Tue Jul 05, 12:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Praluent® (alirocumab) for the treatment of uncontrolled low-density lipoprotein (LDL) cholesterol, in certain adult patients with hypercholesterolemia at high cardiovascular risk.
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08), REGN: 368.75 (-6.99)

Momentum Indicators for Drug Manufacturers - Major Equities -- Sanofi, TherapeuticsMD, Immune Pharma, and Heron Therapeutics
PR Newswire - Thu Jun 30, 6:40AM CDT
On Wednesday, June 29, 2016, the NASDAQ Composite ended the trading session at 4,779.25, up 1.86%; the Dow Jones Industrial Average advanced 1.64%, to finish at 17,694.68; and the S&P 500 closed at 2,070.77, up 1.70%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Sanofi (NYSE: SNY), TherapeuticsMD Inc. (NYSE MKT: TXMD), Immune Pharmaceuticals Inc. (NASDAQ: IMNP), and Heron Therapeutics Inc. (NASDAQ: HRTX). Learn more about these stocks by accessing their free trade alerts at:
HRTX: 17.88 (-0.12), TXMD: 8.11 (-0.01), IMNP: 0.53 (+0.07), SNY: 42.50 (+1.08)

Sanofi-Aventis Set to Possibly Pullback After Yesterday's Rally of 2.15%
Comtex SmarTrend(R) - Wed Jun 29, 2:11PM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $41.08 to a high of $41.68. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $40.62 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 42.50 (+1.08)

Pfizer's PCSK9 Inhibitor Tops Two Additional Phase III Studies
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 10:09AM CDT
Pfizer's (PFE) bococizumab met the primary endpoints in two phase III studies in patients at high and very high risk for cardiovascular events.
PFE: 36.24 (+0.09), AMGN: 161.96 (+1.78), SNY: 42.50 (+1.08), REGN: 368.75 (-6.99)

Sanofi Inks Deal to Swap Business with Boehringer Ingelheim
Zacks Equity Research - Zacks Investment Research - Mon Jun 27, 7:15AM CDT
Sanofi (SNY) signed contracts with Boehringer Ingelheim for the strategic transaction initiated in Dec 2015 regarding an exchange of their businesses.
ANIP: 55.73 (+0.35), PFE: 36.24 (+0.09), RTRX: 18.57 (+0.10), SNY: 42.50 (+1.08)

New Four-Strain Influenza Vaccine, VaxigripTetra(TM), Regulatory Dossier from Sanofi Pasteur Now Approved in Europe
PR Newswire Europe - Thu Jun 23, 6:57AM CDT
LYON, France, June 23, 2016 /PRNewswire/ --
SNY: 42.50 (+1.08)

Look for Shares of Sanofi-Aventis to Potentially Pullback after Yesterday's 1.26% Rise
Comtex SmarTrend(R) - Wed Jun 22, 11:58AM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $39.99 to a high of $40.61. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $39.94 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 42.50 (+1.08)

Watch for Sanofi-Aventis to Potentially Pullback After Gaining 1.26% Yesterday
Comtex SmarTrend(R) - Wed Jun 22, 11:56AM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $39.99 to a high of $40.61. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $39.94 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 42.50 (+1.08)

Merck's Biosimilar Version of Lantus Tops Phase III Studies
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 5:14PM CDT
Merck (MRK) announced encouraging data from two phase III studies on MK-1293 for the treatment of type I and type II diabetes.
MRK: 59.60 (+0.26), LLY: 79.67 (+0.53), BMY: 76.20 (+0.81), SNY: 42.50 (+1.08)

Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting
CNW Group - Sat Jun 11, 10:01AM CDT
Sanofi announced today the release of the new real world data assessing the use of Toujeo(®) (insulin glargine injection 300 Units/mL). The U.S. Predictive Health Intelligence Environment (PHIE) database, containing a substantial amount of patient level information, was analyzed to assess Toujeo in this real life setting. The study examined electronic health records to assess the change in HbA(1c) (average blood sugar levels) and occurrence of hypoglycemia in patients up to 6 months after switching to Toujeo from another basal insulin. The results of the study were presented on June 11 at the American Diabetes Association 76(th) Scientific Sessions in New Orleans, LA, U.S.A.
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)

Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
Globe Newswire - Wed Jun 08, 5:43AM CDT
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
MDVN: 62.15 (-0.08), SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)

Regeneron, Sanofi Report Positive Dupilumab Phase III Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:52AM CDT
Regeneron (REGN) and Sanofi reported that a phase III study on dupilumab in moderate-to-severe atopic dermatitis patients met the primary and secondary endpoints.
ANIP: 55.73 (+0.35), BMY: 76.20 (+0.81), SNY: 42.50 (+1.08), REGN: 368.75 (-6.99)

Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
PR Newswire - Mon Jun 06, 12:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a one-year Phase 3 study, known as LIBERTY AD CHRONOS, evaluating investigational dupilumab met its primary and key secondary endpoints. In the study, dupilumab with topical corticosteroids (TCS) was compared to TCS alone in moderate-to-severe atopic dermatitis (AD) adult patients. Patients in the study were inadequately controlled by topical corticosteroids (TCS) with or without topical calcineurin inhibitors (TCI). Dupilumab with TCS significantly improved measures of overall disease severity at 16 and 52 weeks, when compared to placebo with TCS.
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08), REGN: 368.75 (-6.99)

Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
Globe Newswire - Wed Jun 01, 1:15PM CDT
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
MDVN: 62.15 (-0.08), SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)

Regeneron Reports Interim Data on Cholesterol Lowering Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:00AM CDT
Regeneron (REGN) presented positive interim data from a phase II proof-of-concept study on evinacumab for homozygous familial hypercholestrolemia.
ANIP: 55.73 (+0.35), AMGN: 161.96 (+1.78), SNY: 42.50 (+1.08), REGN: 368.75 (-6.99)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...

Celebree Gains Franchise Momentum: A New Frontier

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Montessori and Tech: A New Era of Integration

Reimagining Montessori with Technology Let's take a stroll down the road less traveled—the intersection of Montessori education and tech. For over a century, Montessori schools have valued individual child development, autonomy, and a purpose-driven environment. But let's face it, their technology hasn't always had the same handcrafted finesse. That's where illumine...

New American Funding Expands in Carolinas with Mullinix Move

The Gathering of Mortgage Titans You don't just waltz into the mortgage world with a $2 billion track record and expect folks not to notice. Will Mullinix, a name that's become synonymous in the Carolinas with mortgage mastery, has decided to bring his influential Mullinix Mortgage Group under the banner of New American Funding. Talk about a power play. This bold strategy...

Simple Home Upgrades That Boost Value Fast

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Skiptown Expands in Georgia Amid Growing Demand

With the pet care industry barking up a storm lately, Skiptown is ramping up efforts to expand its presence in Georgia. The tech-enabled dog care franchise already has a paw print in Atlanta, but it's sniffing out new opportunities across the state. Now they're on the hunt for franchise owners who can bring this modern approach to more communities. Why Georgia? The Growth...

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

Dr. Anderson’s Journey: Leadership with Faith and Service

A Life Shaped by Service Dr. Howard Anderson isn't just another name in a glossy award roster—he's a powerhouse of leadership, a chaplain of compassion, and a soldier in spirit. Honored as a Pinnacle Professional Member of The Inner Circle of Excellence, his recognition feels less like an accolade and more like a testament to a life committed to serving others. The...